The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma
Abstract
CONTEXT: After unsuccessful surgery, medullary thyroid carcinoma (MTC) may be fatal or remain stable for decades, and precise survival predictors are needed. OBJECTIVE: This study assesses the prognostic value of calcitonin and carcinoembryonic antigen (CEA) doubling-times (DT). DESIGN: This is a retrospective study on 65 MTC patients from 2.9-29.5 yr after surgery. SETTING: Data registered in the database of the French Neuroendocrine Tumor Group were analyzed anonymously. PATIENTS: All patients had abnormal calcitonin levels after total thyroidectomy and bilateral lymph node dissection. INTERVENTION: Calcitonin and CEA serum levels were measured during routine disease follow-up. MAIN OUTCOME MEASURE: To assess DT as prognostic factors, a patient population was extracted from the database. RESULTS: When calcitonin DT was less than 6 months, 5- and 10-yr survivals were three of 12 (25%) and one of 12 (8%), respectively; when between 6 months and 2 yr, 5- and 10-yr survivals were 11 of 12 (92%) and three of eight (37%), whereas all 41 patients with calcitonin DT greater than 2 yr were alive at the end of the study. Tumor-Node-Metastasis (TNM) stage, European Organization for Research and Treatment of Cancer (EORTC) score, and calcitonin DT were significant predictors of survival by univariate analysis, but only calcitonin DT remained an independent predictor of survival by multivariate analysis (P = 0.002) with a proportion of variance explained (PVE) of 37.4%. Calcitonin DT was a better predictor than CEA (PVE 63.3% and 47.0%, respectively). Calcitonin DT calculated using only the first four measurements was also an independent predictor of survival (P < 0.000001; PVE 40.4%). CONCLUSION: Calcitonin DT may be superior to initial clinical staging and among the most powerful prognostic indicators in MTC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kebebew, E., Ituarte, P. H. G., Siperstein, A. E., Duh, Q.-Y., & Clark, O. H. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z · Cited by 684
Modigliani, E., Cohen, R., Campos, J., Conte‐Devolx, B., Maes, B., Boneu, A., Schlumberger, M., Bigorgne, J., Dumontier, P., Leclerc, L., et al. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00392.x · Cited by 570
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group
Byar, D. P., Green, S. B., Dor, P., Williams, E. D., Colon, J., van Gilse, H. A., Mayer, M., Sylvester, R. J., & Van Glabbeke, M. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90291-3 · Cited by 554
EXPLAINED VARIATION IN SURVIVAL ANALYSIS
SCHEMPER, M., & STARE, J. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19961015)15:19<1999::aid-sim353>3.0.co;2-d · Cited by 220
Dottorini, M. E., Assi, A., Sironi, M., Sangalli, G., Spreafico, G., & Colombo, L. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960415)77:8<1556::aid-cncr20>3.0.co;2-y · Cited by 211
SAMAAN, N. A., SCHULTZ, P. N., & HICKEY, R. C. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-4-801 · Cited by 167
(GETC), A. T. G. D. D. T. A. C., Schlumberger, M., Abdelmoumene, N., Delisle, M., & Couette, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.73 · Cited by 167
Busnardo, B., Girelli, M. E., Simioni, N., Nacamulli, D., & Busetto, E. (1984) · Cancer · doi:10.1002/1097-0142(19840115)53:2<278::aid-cncr2820530216>3.0.co;2-z · Cited by 159
Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring
Bidart, J.-M., Thuillier, F., Augereau, C., Chalas, J., Daver, A., Jacob, N., Labrousse, F., & Voitot, H. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.10.1695 · Cited by 159
Miyauchi, A., Onishi, T., Morimoto, S., Takai, S., Matsuzuka, F., Kuma, K., Maeda, M., & Kumahara, Y. (1984) · Annals of Surgery · doi:10.1097/00000658-198404000-00014 · Cited by 118
Cited by
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Chen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
Biomarker-Based Risk Stratification for Previously Untreated Medullary Thyroid Cancer
Machens, A., & Dralle, H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2368 · Cited by 385
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J.-F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8471 · Cited by 351
Self-citationMultiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Wells, S. A., Pacini, F., Robinson, B. G., & Santoro, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1204 · Cited by 338
for the German Societies of General and Visceral Surgery; Endocrinology; Nuclear Medicine; Pathology; Radiooncology; Oncological Hematology; and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V., Dralle, H., Musholt, T. J., Schabram, J., Steinmüller, T., Frilling, A., Simon, D., Goretzki, P. E., Niederle, B., Scheuba, C., et al. (2013) · Langenbeck's Archives of Surgery · doi:10.1007/s00423-013-1057-6 · Cited by 279
Laure Giraudet, A., Al Ghulzan, A., Aupérin, A., Leboulleux, S., Chehboun, A., Troalen, F., Dromain, C., Lumbroso, J., Baudin, E., & Schlumberger, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0667 · Cited by 272
Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0355 · Cited by 265
Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Biochemical Testing in Thyroid Disorders
Esfandiari, N. H., & Papaleontiou, M. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.04.002 · Cited by 50
Calcitonin as a biomarker of C cell disease: recent achievements and current challenges
Costante, G., & Meringolo, D. (2020) · Endocrine · doi:10.1007/s12020-019-02183-6 · Cited by 41
Metadata
- Authors
- Barbet, J., Campion, L., Kraeber-Bodéré, F., & Chatal, J.-F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-11
- Volume
- 90
- Issue
- 11
- Pages
- 6077-6084
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2146044942
- Cited by
- 407
- References
- 21
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.